| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director | CSO, Chairman +1 more
4 companies
Glynn Wilson is CSO, Chairman at BNKK and has filed Form 4s across 4 companies. Glynn Wilson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.1M at current prices.
The biggest single holding is BNKK (~$1.0M) as CSO, Chairman. The BNKK filings lean toward selling, a net 50,000 shares.
Glynn Wilson has 22 Form 4 filings on record from November 2015 to October 2026, across 4 companies: Director at Cadrenal Therapeutics (CVKD), 2023–2026; Chief Executive Officer at Caring Brands (CABR), 2025–2026; Former CSO, Chairman at Bonk (BNKK), 2020–2024, and 1 more.
The 30 reported transactions were 11 option or other derivative awards, 8 stock awards, 5 dispositions back to the company and 3 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $140K.
The only open-market sale was 50,000 shares of BNKK at an average $2.79 on July 26, 2021, about $140K. Twelve months later BNKK was down 71%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 26, 2021 | BNKK Bonk, Inc. | Chief Science Officer | Sell | 50,000 | $2.79 | $139,500.00 | -6.3% | 0.0% | -70.7% |